{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:29:17Z","timestamp":1777922957630,"version":"3.51.4"},"reference-count":28,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:p>\n                    Tedizolid activity was compared with other agents with oral and intravenous formulations against community-acquired methicillin-resistant\n                    <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                    (CA-MRSA). Tedizolid (MIC\n                    <jats:sub>50\/90<\/jats:sub>\n                    , 0.12\/0.12\u2009mg\/L; 100.0% susceptible) was the most potent agent tested against CA-MRSA and subsets from adult and pediatric patients. Tedizolid minimum inhibitory concentrations (MICs) were twofold to fourfold lower than daptomycin (MIC\n                    <jats:sub>50\/90<\/jats:sub>\n                    , 0.25\/0.5\u2009mg\/L; 99.9\u2013100% susceptible) and fourfold to eightfold lower than linezolid (MIC\n                    <jats:sub>50\/90<\/jats:sub>\n                    , 1\/1\u2009mg\/L; 100.0% susceptible), ceftaroline (MIC\n                    <jats:sub>50\/90<\/jats:sub>\n                    , 0.5\u20131\/1\u2009mg\/L; 96.6\u201398.8% susceptible), and vancomycin (MIC\n                    <jats:sub>50\/90<\/jats:sub>\n                    , 0.5\u20131\/1\u2009mg\/L; 100.0% susceptible) against CA-MRSA and subsets. Clindamycin resistance rates among CA-MRSA from pediatric and adult patients were 18.3\u201319.1% (13.4\u201314.2% constitutive, 4.9\u20136.4% inducible) and 36.2\u201337.6% (29.8\u201330.1% constitutive, 6.4\u20137.5% inducible), respectively. Tetracycline (90.4\u201396.4% susceptible) and trimethoprim\u2013sulfamethoxazole (96.2\u2013100.0% susceptible) were active against CA-MRSA or subsets, whereas erythromycin (83.8\u201389.4% nonsusceptible) and levofloxacin (50.2\u201370.8% nonsusceptible) had limited activities. Tedizolid had MIC\n                    <jats:sub>50\/90<\/jats:sub>\n                    values of 0.12\/0.12\u2009mg\/L against CA-MRSA showing clindamycin constitutive-resistance and recovered from adult or pediatric patients. Tedizolid had potent activities against CA-MRSA, regardless of clindamycin phenotype or patient population. Tedizolid may be considered for the treatment of ABSSSI in adults. Further studies are warranted for the clinical development in the pediatric population.\n                  <\/jats:p>","DOI":"10.1089\/mdr.2018.0410","type":"journal-article","created":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T15:05:17Z","timestamp":1548774317000},"page":"938-943","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["<i>In Vitro<\/i>\n                    Activity of Tedizolid in Comparison with Other Oral and Intravenous Agents Against a Collection of Community-Acquired Methicillin-Resistant\n                    <i>Staphylococcus aureus<\/i>\n                    (2014\u20132015) in the United States"],"prefix":"10.1177","volume":"25","author":[{"given":"Michael A.","family":"Pfaller","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul R.","family":"Rhomberg","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,7,11]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.spid.2004.01.003"},{"key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"e242","DOI":"10.1097\/INF.0b013e318286c612","article-title":"The antibiotic resistance and prescribing in European Children project: a neonatal and pediatric antimicrobial web-based point prevalence survey in 73 hospitals worldwide","volume":"32","author":"Versporten A.","year":"2013","unstructured":"Versporten A., , Sharland M., , Bielicki J., , Drapier N., , Vankerckhoven V., , Goossens H.; ARPECProjectGroup Members. 2013. The antibiotic resistance and prescribing in European Children project: a neonatal and pediatric antimicrobial web-based point prevalence survey in 73 hospitals worldwide. Pediatr. Infect. Dis. J. 32:e242\u2013e253.","journal-title":"Pediatr. Infect. Dis. J"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2017.05.019"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2016.174"},{"key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"e01043","DOI":"10.1128\/AAC.01043-17","article-title":"Antimicrobial susceptibility trends among Staphylococcus aureus from U. S. hospitals: results from 7 years of the ceftaroline (AWARE) surveillance program (2010\u20132016)","volume":"61","author":"Sader H.S.","year":"2017","unstructured":"Sader H.S., , Mendes R.E., , Streit J.M., , and Flamm R.K.. 2017. Antimicrobial susceptibility trends among Staphylococcus aureus from U. S. hospitals: results from 7 years of the ceftaroline (AWARE) surveillance program (2010\u20132016). Antimicrob. Agents Chemother., 61:e01043.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir531"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcl.2013.12.004"},{"key":"e_1_3_4_9_2","first-page":"64","article-title":"Community-associated MRSA in the pediatric primary care setting","volume":"34","author":"Hinckley J.","year":"2008","unstructured":"Hinckley J., , and Allen P.J.. 2008. Community-associated MRSA in the pediatric primary care setting. Pediatr. Nurs. 34:64\u201371.","journal-title":"Pediatr. Nurs"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00081-09"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp241"},{"key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.diagmicrobio.2014.08.011","article-title":"Results of the Surveillance of Tedizolid Activity and Resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe","volume":"81","author":"Sahm D.F.","year":"2015","unstructured":"Sahm D.F., , Deane J., , Bien P.A., , Locke J.B., , Zuill D.E., , Shaw K.J., , and Bartizal K.F.. 2015. Results of the Surveillance of Tedizolid Activity and Resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe. Diagn. Microbiol. Infect. Dis. 81:112\u2013118.","journal-title":"Diagn. Microbiol. Infect. Dis"},{"key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1128\/AAC.00881-16","article-title":"Activities of tedizolid and linezolid determined by the reference broth microdilution method against 3,032 Gram-positive bacterial isolates collected in Asia-Pacific, Eastern Europe, and Latin American countries in 2014","volume":"60","author":"Pfaller M.A.","year":"2016","unstructured":"Pfaller M.A., , Flamm R.K., , Jones R.N., , Farrell D.J., , and Mendes R.E.. 2016. Activities of tedizolid and linezolid determined by the reference broth microdilution method against 3,032 Gram-positive bacterial isolates collected in Asia-Pacific, Eastern Europe, and Latin American countries in 2014. Antimicrob. Agents Chemother. 60:5393\u20135399.","journal-title":"Antimicrob. Agents Chemother"},{"issue":"1","key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1093\/cid\/cit616","article-title":"Tedizolid for the management of human infections: in vitro characteristics","volume":"58","author":"Locke J.B.","year":"2014","unstructured":"Locke J.B., , Zurenko G.E., , Shaw K.J., , and Bartizal K.. 2014. Tedizolid for the management of human infections: in vitro characteristics. Clin. Infect. Dis. 58,(Suppl 1)::S35\u2013S42.","journal-title":"Clin. Infect. Dis"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40265-015-0352-7","article-title":"Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens","volume":"75","author":"Zhanel G.G.","year":"2015","unstructured":"Zhanel G.G., , Love R., , Adam H., , Golden A., , Zelenitsky S., , Schweizer F., , Gorityala B., , Lagace-Wiens P.R., , Rubinstein E., , Walkty A., , Gin A.S., , Gilmour M., , Hoban D.J., , Lynch J.P., , 3rd, and Karlowsky J.A.. 2015. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. Drugs, 75:253\u2013270.","journal-title":"Drugs"},{"key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"S342","DOI":"10.1093\/cid\/ciy612","article-title":"Multiparameter responses to tedizolid monotherapy and moxifloxacin combination therapy models of children with intracellular tuberculosis","volume":"67","author":"Deshpande D.","year":"2018","unstructured":"Deshpande D., , Srivastava S., , Nuermberger E., , Koeuth T., , Martin K.R., , Cirrincione K.N., , Lee P.S., , and Gumbo T.. 2018. Multiparameter responses to tedizolid monotherapy and moxifloxacin combination therapy models of children with intracellular tuberculosis. Clin. Infect. Dis. 67:S342\u2013S348.","journal-title":"Clin. Infect. Dis"},{"key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jiac.2018.01.010","article-title":"Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan\u2014results of a randomised, multicentre phase 3 study","volume":"24","author":"Mikamo H.","year":"2018","unstructured":"Mikamo H., , Takesue Y., , Iwamoto Y., , Tanigawa T., , Kato M., , Tanimura Y., , and Kohno S.. 2018. Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan\u2014results of a randomised, multicentre phase 3 study. J. Infect. Chemother. 24:434\u2013442.","journal-title":"J. Infect. Chemother"},{"key":"e_1_3_4_18_2","author":"Sivextro","year":"2018","unstructured":"Sivextro. [Package Insert]. Kenilworth, NJ: Merck & Co., Inc.; 2018. Available at https:\/\/www.merck.com\/product\/usa\/pi_circulars\/s\/sivextro\/sivextro_pi.pdf (accessed January23, 2018).","journal-title":"[Package Insert]"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-4-200802190-00204"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02274-06"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403789"},{"key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.cmi.2017.06.010","article-title":"New and improved? A review of novel antibiotics for Gram-positive bacteria","volume":"23","author":"Abbas M.","year":"2017","unstructured":"Abbas M., , Paul M., , and Huttner A.. 2017. New and improved? A review of novel antibiotics for Gram-positive bacteria. Clin. Microbiol. Infect. 23:697\u2013703.","journal-title":"Clin. Microbiol. Infect"},{"key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ijantimicag.2017.05.006","article-title":"Recently approved antibacterials for methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive pathogens: the shock of the new","volume":"50","author":"David M.Z.","year":"2017","unstructured":"David M.Z., , Dryden M., , Gottlieb T., , Tattevin P., , and Gould I.M.. 2017. Recently approved antibacterials for methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive pathogens: the shock of the new. Int. J. Antimicrob. Agents. 50:303\u2013307.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_4_24_2","unstructured":"CLSI. 2015. M07-A10. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard 10th ed. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_4_25_2","volume-title":"M100-S27. Performance Standards for Antimicrobial Susceptibility Testing: 27th Informational Supplement","author":"CLSI","year":"2017","unstructured":"CLSI. 2017. M100-S27. Performance Standards for Antimicrobial Susceptibility Testing: 27th Informational Supplement. Clinical and Laboratory Standards Institute: Wayne, PA."},{"key":"e_1_3_4_26_2","unstructured":"EUCAST. 2017. Breakpoint tables for interpretation of MIC's and zone diameters. Version 7.1 March 2017. Available at www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_7.1_Breakpoint_Tables.pdf Accessed March2017."},{"key":"e_1_3_4_27_2","unstructured":"Tygacil. 2018. \u201cTygacil\u00ae package insert.\u201d Retrieved October 15 2018. Available at http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?format=PDF&id=491 (accessed January23 2018 )."},{"key":"e_1_3_4_28_2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.diagmicrobio.2016.06.017","article-title":"Antimicrobial susceptibility patterns of community- and hospital-acquired methicillin-resistant Staphylococcus aureus from United States Hospitals: results from the AWARE Ceftaroline Surveillance Program (2012\u20132014)","volume":"86","author":"Sader H.S.","year":"2016","unstructured":"Sader H.S., , Mendes R.E., , Jones R.N., , and Flamm R.K.. 2016. Antimicrobial susceptibility patterns of community- and hospital-acquired methicillin-resistant Staphylococcus aureus from United States Hospitals: results from the AWARE Ceftaroline Surveillance Program (2012\u20132014). Diagn. Microbiol. Infect. Dis. 86:76\u201379.","journal-title":"Diagn. Microbiol. Infect. Dis"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu296"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2018.0410","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2018.0410","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2018.0410","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:34:33Z","timestamp":1777667673000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/mdr.2018.0410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1089\/mdr.2018.0410"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2018.0410","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}